Entero Therapeutics Faces Delisting Concerns

TL;DR

Entero Therapeutics might get delisted, check your shares!

AI Summary

Entero Therapeutics, Inc. filed an 8-K on August 23, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company was formerly known as First Wave BioPharma, Inc. and AzurRx BioPharma, Inc. The filing indicates potential issues with maintaining its listing on the stock exchange.

Why It Matters

This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the stock being removed from trading, impacting investors.

Risk Assessment

Risk Level: high — The company is reporting a notice of delisting or failure to satisfy continued listing rules, indicating significant risk to its stock market presence.

Key Players & Entities

• Entero Therapeutics, Inc. (company) — Registrant
• First Wave BioPharma, Inc. (company) — Former Name
• AzurRx BioPharma, Inc. (company) — Former Name
• August 21, 2024 (date) — Earliest event reported
• August 23, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share ENTO Nasdaq Capital Mark

Filing Documents

• tm2422567d1_8k.htm (8-K) — 27KB
• tm2422567d1_ex99-1.htm (EX-99.1) — 10KB
• tm2422567d1_ex99-1img001.jpg (GRAPHIC) — 8KB
• 0001104659-24-092491.txt ( ) — 222KB
• fwbi-20240821.xsd (EX-101.SCH) — 3KB
• fwbi-20240821_lab.xml (EX-101.LAB) — 33KB
• fwbi-20240821_pre.xml (EX-101.PRE) — 22KB
• tm2422567d1_8k_htm.xml (XML) — 4KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported in a Form 12b-25 Notification of Late Filing filed by Entero Therapeutics, Inc. (the "Company"), on August 15, 2024, the Company is delayed in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q") with the U.S. Securities and Exchange Commission (the "SEC") because it is in the process of engaging a new independent registered public accounting firm. On August 21, 2024, the Company received a notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that, because the Company has not timely filed its Form 10-Q, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires companies with securities listed on Nasdaq to timely file all required periodic reports with the SEC. The Company has sixty (60) days, or until October 21, 2024, to submit a plan to regain compliance with the Rule to Nasdaq. If Nasdaq approves such a plan, it has the discretion to grant the Company an extension of up to 180 calendar days, or until February 17, 2025, to regain compliance with the Rule. The Notice has no immediate effect on the listing or trading of the Company's common stock on the Nasdaq Capital Market. The Company is in the process of engaging a new independent registered public accounting firm and intends to take the necessary steps to regain compliance with the Rule as soon as practicable. On August 23, 2024, the Company issued a press release announcing its receipt of the Notice (the "Press Release"). The Press Release is attached hereto as Exhibit 99.1 and is being filed herewith.

Financial Statements and Exhibits

Financial Statements and Exhibits. 99.1 Press Release, dated August 23, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Entero Therapeutics, Inc. August 23, 2024 By: /s/ James Sapirstein Name: James Sapirstein Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR